Skip to main content

menu
menu
person
Search

Specialty Program

Pain Management

Glycemic Regulation

PCSK9s in Interventional Cardiology

PCSK9s in Medical Preventative

PCSK9s in Lipid Medicine & Atherosclerosis Prevention

PCSK9s in Diabetes Management

PCSK9s: A Multi-Specialty Perspective

Specialty Program

Glycemic Regulation

PCSK9s in Diabetes Management

Specialty Program

Specialty Program

Parkinson's Disease

Specialty Program

Extracorporeal Photopheresis (ECP)

Pain Management

Specialty Program

Atopic Dermatitis

Parkinson's Disease

Pain Management

Glycemic Regulation

Specialty Program

Atopic Dermatitis

Extracorporeal Photopheresis (ECP)

Specialty Program

Atopic Dermatitis

Biosimilars for RA

PCSK9s in Interventional Cardiology

PCSK9s in Medical Preventative

PCSK9s in Lipid Medicine & Atherosclerosis Prevention

PCSK9s in Diabetes Management

PCSK9s: A Multi-Specialty Perspective

MAC Lung Disease

Specialty Program

MAC Lung Disease

close

person

Home
Specialties
- Topics
- Biologics
- Cancer
- Cardiology
- Dermatology
- Diabetes
- Hypothyroidism
- MAC Lung Disease
- Neurology
- Primary Care
Submit A Question

Cyrus Desouza, MBBS

Cyrus Desouza, MBBS

Professor, Internal Medicine Division of Diabetes, Endocrine & Metabolism
University of Nebraska Medical Center
Omaha, Nebraska

What are the physiologic and clinical properties of incretin system-targeting agents?

What are the physiologic and clinical properties of incretin system-targeting agents?

What are the physiologic and clinical properties of incretin system-targeting agents?

Cyrus Desouza, MBBS

What are the multi-factorial effects of GLP-1 RAs?

What are the multi-factorial effects of GLP-1 RAs?

What are the multi-factorial effects of GLP-1 RAs?

Cyrus Desouza, MBBS

What is the physiologic and clinical rationale for combining basal insulin and a GLP-1 RA as a treatment strategy for T2D?

What is the physiologic and clinical rationale for combining basal insulin and a GLP-1 RA as a treatment strategy for T2D?

What is the physiologic and clinical rationale for combining basal insulin and a GLP-1 RA as a treatment strategy for T2D?

Cyrus Desouza, MBBS

Disclaimer:
Copyright © by CMEducation Resources, LLC All rights reserved. Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Clinical Webcasts®

Powered by BROADCASTMED